Matsuyama Red Cross Hospital

Matsuyama, Ehime 790-8524

4 studies enrolling now · 8 studies all time

What they study most

AML Arising From Myelodysplastic Syndrome (MDS), B Cell Lymphoma, Beta-thalassemia, Chronic Lymphocytic Leukemia, Gastroesophageal Junction Adenocarcinoma, Leukemia, Myeloid, Acute, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Metastatic Gastric Adenocarcinoma, Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis, Neovascular Age-Related Macular Degeneration (nAMD)

Studies at this site

• A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma — Recruiting now
• A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — Recruiting now
• A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) — Recruiting now
• A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials — Recruiting now
• A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma — Running, not enrolling
• Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation — Running, not enrolling
• Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma — Running, not enrolling
• Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration — Running, not enrolling